-
Purpose(Empty Backbone) Introduce sgRNA into a lentiviral vector (LentiCRISPR V2) which contains eSpCas9 and puromycin cassette
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 78852 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepLentiCRISPRV2
- Backbone size (bp) 14849
-
Modifications to backboneespcas9: K848A, K1003A, K1060A
-
Vector typeMammalian Expression, Lentiviral, CRISPR
-
Selectable markersPuromycin
-
Tag
/ Fusion Protein
- Cas9-P2A-Puro
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)Stbl3
-
Copy numberHigh Copy
Cloning Information
- Cloning method Restriction Enzyme
Resource Information
-
Supplemental Documents
-
Addgene Notes
-
A portion of this plasmid was derived from a plasmid made byFeng Zhang
-
Articles Citing this Plasmid
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
pLentiCRISPR-E was a gift from Phillip Abbosh (Addgene plasmid # 78852 ; http://n2t.net/addgene:78852 ; RRID:Addgene_78852) -
For your References section:
Differential effects of clinically-relevant N- vs C-terminal truncating CDKN1A mutations on cisplatin sensitivity in bladder cancer. Sikder RK, Ellithi M, Uzzo RN, Weader D, Metz AL, Behbahani A, McKenzie ER, El-Deiry WS, Abbosh PH. Mol Cancer Res. 2020 Dec 3. pii: 1541-7786.MCR-19-1200. doi: 10.1158/1541-7786.MCR-19-1200. 10.1158/1541-7786.MCR-19-1200 PubMed 33272936